Recent developments include OneMedNet regaining Nasdaq compliance, expanding data partnerships, supporting FDA clearance for AI healthcare products, and raising capital through private placements.

• OneMedNet regained compliance with Nasdaq listing rules related to minimum bid price and listing standards as of early 2026 [N1].
• The company expanded autoimmune data capabilities through a partnership with ViuHealth, enhancing its healthcare data offerings [N2].
• OneMedNet supported MlHealth 360 in obtaining FDA clearance for the Scaida BrainCT-ICH AI-enabled healthcare product [N3].
• The company raised approximately $3.7 million in private placement transactions in mid-2025 to support operations and growth [N7].
• OneMedNet expanded Datavant Connect capabilities to enhance healthcare data discovery and analytics [N8].

OneMedNet’s recent partnerships to expand autoimmune data and enhance real-time access to patient data for AI development demonstrate active business development and product relevance. The company’s involvement in supporting FDA clearance for AI-enabled healthcare products indicates potential for integration into clinical workflows. The successful private placements and shareholder loan conversions provide capital to support growth initiatives. Regaining Nasdaq compliance removes a key regulatory hurdle, potentially improving investor confidence and access to capital.

The company reported a net loss of $2.8 million on revenues of $1.36 million in 2025, with liquidity ratios below 1, indicating potential short-term financial stress. Current liabilities significantly exceed current assets, which may constrain operational flexibility. The company faces risks related to maintaining Nasdaq listing compliance, competitive pressures in healthcare IT, and the need to scale revenue to achieve profitability. Dependence on partnerships and regulatory approvals introduces execution risks. The relatively low market price and recent compliance notices highlight ongoing challenges in market perception and financial stability.

OneMedNet’s moat is based on its specialized healthcare data sharing platform and strategic partnerships that enhance access to real-world and multimodal patient data, which are critical for AI development and healthcare analytics. The company’s leadership team combines healthcare IT expertise with medical knowledge, supporting product innovation and market relevance. Its collaborations with entities like ViuHealth and Protege, and involvement in FDA-cleared AI healthcare products, contribute to its competitive positioning. However, the company operates in a competitive and evolving healthcare IT landscape where data access and regulatory compliance are key challenges.

• Nasdaq Listing Compliance Risk: The company recently received a notice for non-compliance with Nasdaq minimum bid price rules and has a 180-day period to regain compliance, with potential delisting risk if not resolved [N1][S1].
• Financial Liquidity Risk: As of December 31, 2025, the company’s current ratio was 0.43 and cash ratio 0.12, indicating current liabilities exceed current assets, which may impact operational liquidity [S1].
• Profitability and Revenue Growth Risk: The company reported a net loss and modest revenue in 2025, requiring execution on growth strategies to improve financial performance [S1].
• Regulatory and Execution Risk: The company’s business depends on regulatory approvals and successful partnerships to expand data capabilities and product offerings, which carry inherent uncertainties [N3][N2].

• OneMedNet Corp is a healthcare IT company focused on healthcare data sharing and analytics solutions.
• The company is publicly traded on Nasdaq under the ticker ONMD and also has redeemable warrants (ONMDW).
• As of December 31, 2025, OneMedNet reported revenues of $1.359 million and a net loss of $2.801 million, with basic and diluted EPS of -$0.06 per share [S1].
• The company had cash and cash equivalents of $585,000 and current assets of $2.095 million against current liabilities of $4.825 million as of December 31, 2025, resulting in a current ratio of 0.43 and a cash ratio of 0.12 [S1].
• OneMedNet has a board of eight directors with a majority being independent, including experienced executives in healthcare IT, finance, and medical fields [S1].
• The CEO, Aaron Green, has over 20 years of healthcare IT leadership experience, including roles at Optum and Change Healthcare [S1].
• The company has engaged in multiple partnerships to expand its healthcare data capabilities, including with ViuHealth to expand autoimmune data and with Protege to enhance real-time access to multimodal patient data for AI development [N2][N8].
• OneMedNet supported MlHealth 360 in obtaining FDA clearance for the Scaida BrainCT-ICH product, indicating involvement in AI-enabled healthcare solutions [N3].
• The company raised approximately $3.7 million in private placement transactions in mid-2025, including convertible shareholder loans and stock issuances to directors and related parties [N7][S1].
• OneMedNet regained compliance with Nasdaq listing rules related to minimum bid price and listing standards as of early 2026 [N1][S1].
• The company’s shares outstanding were approximately 52.2 million as of March 27, 2026 [S1].
• OneMedNet’s business model involves providing healthcare data sharing and analytics platforms to improve healthcare outcomes and support AI development in healthcare [N2][N8].